MX2010004312A - Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso. - Google Patents

Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso.

Info

Publication number
MX2010004312A
MX2010004312A MX2010004312A MX2010004312A MX2010004312A MX 2010004312 A MX2010004312 A MX 2010004312A MX 2010004312 A MX2010004312 A MX 2010004312A MX 2010004312 A MX2010004312 A MX 2010004312A MX 2010004312 A MX2010004312 A MX 2010004312A
Authority
MX
Mexico
Prior art keywords
ksp kinesin
kinesin activity
spiro
condensed
thiadiazole derivatives
Prior art date
Application number
MX2010004312A
Other languages
English (en)
Inventor
M Arshad Siddiqui
Chaoyang Dai
Umar Faruk Mansoor
Liping Yang
Lalalnthi Dilrukshi Vitharana
Angie R Angeles
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40220231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010004312(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010004312A publication Critical patent/MX2010004312A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I), más adelante, (en donde X, R1, R2, R3, p, E, anillo A, y anillo 8 son como se definen en la presente); la presente invención también se refiere a composiciones (incluyendo composiciones farmacéuticamente aceptables) que comprenden estos compuestos, solos y en combinación con uno o más agentes terapéuticos adicionales, y a métodos para su uso en la inhibición de la actividad de cinesina KSP, y para tratar enfermedades o trastornos proliferativos celulares asociados con la actividad de cinesina KSP. (Ver fórmula I).
MX2010004312A 2007-10-19 2008-10-16 Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso. MX2010004312A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98128807P 2007-10-19 2007-10-19
PCT/US2008/080164 WO2009052288A1 (en) 2007-10-19 2008-10-16 Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity

Publications (1)

Publication Number Publication Date
MX2010004312A true MX2010004312A (es) 2010-07-05

Family

ID=40220231

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004312A MX2010004312A (es) 2007-10-19 2008-10-16 Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso.

Country Status (19)

Country Link
US (1) US8796460B2 (es)
EP (1) EP2220061B1 (es)
JP (1) JP5455915B2 (es)
KR (1) KR20100072267A (es)
CN (2) CN103694258B (es)
AR (1) AR068888A1 (es)
AU (1) AU2008312401C1 (es)
BR (1) BRPI0818605A2 (es)
CA (1) CA2702922C (es)
CL (1) CL2008003063A1 (es)
CO (1) CO6321241A2 (es)
ES (1) ES2565983T3 (es)
IL (1) IL205184A0 (es)
MX (1) MX2010004312A (es)
PE (1) PE20091349A1 (es)
RU (1) RU2010119635A (es)
TW (1) TW200934785A (es)
WO (1) WO2009052288A1 (es)
ZA (1) ZA201002701B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
WO2009050242A2 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
CA2705414C (en) 2007-10-19 2016-05-24 Boehringer Ingelheim International Gmbh Substituted piperidino-dihydrothienopyrimidines
ATE537175T1 (de) 2007-10-19 2011-12-15 Boehringer Ingelheim Int Neue piperazino-dihydrothienopyrimidin-derivate
WO2010132520A1 (en) * 2009-05-13 2010-11-18 Schering Corporation Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors
US8748626B2 (en) * 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
WO2012009097A1 (en) 2010-06-17 2012-01-19 Cytokinetics, Inc. Methods of treating lung disease
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
EP2750508A4 (en) 2011-08-30 2015-01-14 Univ Wayne State COMPOUNDS AND THERAPEUTIC METHODS
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN110041349B (zh) * 2019-05-15 2021-06-01 湖南科技大学 一种含螺二氢嘧啶衍生物及其制备方法和应用
CN111529525A (zh) * 2020-05-15 2020-08-14 淮安市厚沐医疗技术咨询中心 一种Gab1抑制剂用于治疗胆管癌的用途
CN111358786A (zh) * 2020-05-15 2020-07-03 淮安市厚沐医疗技术咨询中心 一种Gab1抑制剂在治疗胆管癌方面的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1454903T3 (da) 2001-12-11 2010-11-22 Kyowa Hakko Kirin Co Ltd Thiadiazolinderivater til behandling af cancer
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
AU2003245453B2 (en) 2002-06-14 2008-08-14 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
CA2500848A1 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1581497A4 (en) 2002-12-20 2009-03-18 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
JP4590270B2 (ja) 2002-12-20 2010-12-01 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
US20040192739A1 (en) * 2003-01-16 2004-09-30 David Solow-Cordero Methods of treating conditions associated with an Edg-2 receptor
AR050920A1 (es) 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
WO2004087050A2 (en) 2003-03-28 2004-10-14 Merck & Co., Inc. Mitotic kinesin inhibitors
ES2394850T3 (es) * 2003-04-18 2013-02-06 Kyowa Hakko Kirin Co., Ltd. Inhibidor de cinesina mitótica
WO2004111023A1 (ja) 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン－１－オキシド誘導体
WO2004112699A2 (en) 2003-06-12 2004-12-29 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1636182A4 (en) 2003-06-12 2008-09-03 Merck & Co Inc PRODRUGS OF INHIBITORS FROM MITOTIC KINESINE
EP1656140A4 (en) 2003-08-13 2009-03-04 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
DE602004019229D1 (de) 2003-08-15 2009-03-12 Merck & Co Inc Inhibitoren von mitotischem kinesin
CA2533889A1 (en) 2003-08-15 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
AR045342A1 (es) 2003-08-15 2005-10-26 Merck & Co Inc Inhibidores de quinesina mitotica
WO2005017190A2 (en) 2003-08-15 2005-02-24 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2542034A1 (en) 2003-10-10 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivatives
WO2005060654A2 (en) * 2003-12-19 2005-07-07 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2005092011A2 (en) 2004-03-22 2005-10-06 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2005102996A2 (en) 2004-04-19 2005-11-03 Merck & Co., Inc. A process for the preparation of 2,2-disubstituted pyrroles
DE102004021637A1 (de) 2004-05-03 2005-12-01 Merck Patent Gmbh Dihydrobenzothiophene
DE102004031656A1 (de) 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
CA2571824A1 (en) 2004-07-01 2006-01-19 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1773326A4 (en) 2004-07-01 2009-07-22 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
RU2007103816A (ru) 2004-07-01 2008-08-10 Мерк энд Ко., Инк. (US) Ингибиторы митотического кинезина
US7718687B2 (en) 2004-07-01 2010-05-18 Merck Sharp & Dohme Corp., Prodrugs of mitotic kinesin inhibitors
AU2005263969A1 (en) 2004-07-22 2006-01-26 Astrazeneca Ab Fused pyrimidones useful in the treatment and the prevention of cancer
WO2006023083A1 (en) 2004-08-12 2006-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2576168A1 (en) 2004-08-18 2006-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2008510013A (ja) 2004-08-18 2008-04-03 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
JP2008509976A (ja) 2004-08-18 2008-04-03 アストラゼネカ アクチボラグ 選択された縮合複素環及びその使用
EP1791969A4 (en) 2004-09-13 2008-07-02 Merck & Co Inc METHOD FOR THE TREATMENT OF CANCER
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US20080045492A1 (en) 2004-12-21 2008-02-21 Coleman Paul J Mitotic Kinesin Inhibitors
US7595337B2 (en) 2005-02-10 2009-09-29 Merck & Co. Inc. Mitotic kinesin inhibitors
DE102005010000A1 (de) 2005-03-04 2006-09-07 Merck Patent Gmbh Indane
KR20070113267A (ko) 2005-03-09 2007-11-28 쉐링 코포레이션 Ｋｓｐ 키네신 활성 억제용 화합물
CN101171052A (zh) 2005-03-09 2008-04-30 先灵公司 抑制ksp驱动蛋白活性的化合物
US7608643B2 (en) 2005-03-09 2009-10-27 Schering Corporation Compounds for inhibiting KSP kinesin activity
US7625936B2 (en) 2005-03-16 2009-12-01 Merck & Co. Inc. Mitotic kinesin inhibitors
EP1861097A4 (en) 2005-03-16 2010-01-13 Merck & Co Inc MITOTIC INHIBITORS OF KINESIN
JP2008137893A (ja) 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
JP2008150291A (ja) 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
CA2602559A1 (en) 2005-03-22 2006-09-28 Kyowa Hakko Kogyo Co., Ltd. Agent for treatment of hematopoietic tumor
TW200714593A (en) 2005-03-22 2007-04-16 Kyowa Hakko Kogyo Kk Agent for treatment of solid tumor
JP2008535839A (ja) 2005-04-07 2008-09-04 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
UA95907C2 (en) * 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
DE102005027169A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinolinderivate
DE102005027170A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Substituierte Tetrahydrochinoline
DE102005027168A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
US7910611B2 (en) 2005-06-24 2011-03-22 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for restenosis
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
CA2654722A1 (en) * 2006-06-09 2007-12-21 Wyeth Thiadiazole compounds and methods of use thereof
WO2008042928A2 (en) 2006-10-03 2008-04-10 Array Biopharma, Inc. Oxadiazole and thiadiazole derivatives as mitotic kinesin inhibitors and methods of use thereof
US20110171172A1 (en) * 2007-11-07 2011-07-14 Siddiqui M Arshad Compounds for inhibiting ksp kinesin activity
CA2702990A1 (en) * 2007-11-09 2009-05-14 Schering Corporation Compounds for inhibiting ksp kinesin activity
CN101903343A (zh) 2007-11-09 2010-12-01 先灵公司 用于抑制ksp驱动蛋白活性的化合物
WO2010132520A1 (en) 2009-05-13 2010-11-18 Schering Corporation Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors

Also Published As

Publication number Publication date
CN101903365B (zh) 2014-02-05
AU2008312401C1 (en) 2014-07-10
AU2008312401B2 (en) 2014-03-06
BRPI0818605A2 (pt) 2015-04-22
RU2010119635A (ru) 2011-11-27
CO6321241A2 (es) 2011-09-20
PE20091349A1 (es) 2009-09-07
TW200934785A (en) 2009-08-16
KR20100072267A (ko) 2010-06-30
ES2565983T3 (es) 2016-04-08
EP2220061A1 (en) 2010-08-25
JP2011500714A (ja) 2011-01-06
CN101903365A (zh) 2010-12-01
CN103694258A (zh) 2014-04-02
AU2008312401A1 (en) 2009-04-23
CA2702922C (en) 2018-01-16
CA2702922A1 (en) 2009-04-23
WO2009052288A1 (en) 2009-04-23
CL2008003063A1 (es) 2010-01-04
ZA201002701B (en) 2011-04-28
IL205184A0 (en) 2010-11-30
EP2220061B1 (en) 2016-02-17
US8796460B2 (en) 2014-08-05
JP5455915B2 (ja) 2014-03-26
CN103694258B (zh) 2016-01-13
AR068888A1 (es) 2009-12-16
US20110123435A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
MX2010004312A (es) Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso.
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
TW200740434A (en) A prophylactic and/or therapeutic agent for for sleep disorders
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
UA105390C2 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
IL175714A0 (en) Quinazolinone compounds as anticancer agents
TW200716628A (en) Novel compounds
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
WO2004108715A8 (en) 3-aryloxy and 3-heteroaryloxy substituted benzo(b) thiophenes as therapeutic agents with pi3k activity
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
TW200626158A (en) Naphthaline derivatives
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: MICROSOFT TECHNOLOGY LICENSING, LLC

FG Grant or registration